Compare Endeavour Silver Corp (EXK) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Endeavour Silver Corp vs GSK plc — how do they compare? Endeavour Silver Corp trades at $8.71 (market cap $2.54B), while GSK plc trades at $46.63 (market cap $91.88B). The key difference: GSK plc is far larger — about 36.2× Endeavour Silver Corp's market cap, and GSK plc pays a 3.9% dividend while Endeavour Silver Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Endeavour Silver Corp for 25 Days and GSK plc for 93 Days on average.
| EXK | GSK | |
|---|---|---|
Market Cap | $2.54B | $91.88B |
Volume | 7,077,330 | 7,730,529 |
Sector | Basic Materials | Health |
52-Week High | $14.12 | $61.18 |
52-Week Low | $7.07 | $43.24 |
Typical Hold Time | 25 Days | 93 Days |
Enterprise Value | $2.54B | $111.88B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Endeavour Silver (EXK) trades at $8.72, up 4.81% today, showing mixed technical signals with bearish moving averages but neutral oscillators. The company demonstrates improving fundamentals with Q1 2026 earnings beating expectations and projected revenue growth from $468M to $737M in 2026. Recent operational developments include Terronera mine resumption and Kolpa expansion, though mechanical issues at Guanacevi mine present near-term challenges.
EXK presents a growth story with strong analyst support (78.57% buy rating) and improving profitability, but faces operational risks and high valuation multiples. The stock's outlook depends on successful mine execution and silver price stability, with technical resistance at $9.00 providing a near-term hurdle for further upside.
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
